1,25-dihydroxyvitamin D3-conditioned CD11c+ dendritic cells are effective initiators of CNS autoimmune disease

Frontiers in Immunology

Volumn 6, Issue NOV, 2015, Pages

  Besusso, Dario ^a,b   Saul, Louise ^a,b   Leech, Melanie D ^a,b   O'Connor, Richard A ^a,b   MacDonald, Andrew S ^c   Anderton, Stephen M ^a,b   Mellanby, Richard J ^a,b,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Dendritic cell; Experimental autoimmune encephalomyelitis; Multiple sclerosis; T cell; Vitamin D

Indexed keywords

ALPHA INTEGRIN; CALCITRIOL; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 17; MYELIN BASIC PROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; DENDRITIC CELL; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FLUORESCENCE ACTIVATED CELL SORTING; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

EID: 84949544640     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00575     Document Type: Article

References (49)

1. Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol (2012) 3:233. doi: 10.3389/fimmu.2012.00233.
2. Gordon JR, Ma Y, Churchman L, Gordon SA, Dawicki W. Regulatory dendritic cells for immunotherapy in immunologic diseases. Front Immunol (2014) 5:7. doi:10.3389/fimmu.2014.00007.
3. Ioannidis JP, Karassa FB, Druyts E, Thorlund K, Mills EJ. Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol (2013) 9(11):665-73. doi:10.1038/nrrheum.2013.134.
4. Adorini L. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann N Y Acad Sci (2003) 987:258-61. doi:10.1111/j.1749-6632.2003.tb06057.x.
5. Griffin MD, Lutz W, Phan VA, Bachman LA, McKean DJ, Kumar R. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A (2001) 98(12):6800-5. doi:10.1073/pnas.121172198.
6. Ferreira GB, van Etten E, Verstuyf A, Waer M, Overbergh L, Gysemans C, et al. 1,25-dihydroxyvitamin D3 alters murine dendritic cell behaviour in vitro and in vivo. Diabetes Metab Res Rev (2011) 27(8):933-41. doi:10.1002/dmrr.1275.
7. Naranjo-Gomez M, Raich-Regue D, Onate C, Grau-Lopez L, Ramo-Tello C, Pujol-Borrell R, et al. Comparative study of clinical grade human tolerogenic dendritic cells. J Transl Med (2011) 9:89. doi:10.1186/1479-5876-9-89.
8. Doni F, Manfredi M, Piemonti C, Staffiere E, Todd S, Rimondini A, et al. New onset atrial flutter termination by overdrive transoesophageal pacing: effects of different protocols of stimulation. Europace (2000) 2(4):292-6. doi:10.1053/eupc.2000.0126.
9. Unger WW, Laban S, Kleijwegt FS, van der Slik AR, Roep BO. Induction of Treg by monocyte-derived DC modulated by vitamin D3 or dexamethasone: differential role for PD-L1. Eur J Immunol (2009) 39(11):3147-59. doi:10.1002/eji.200839103.
10. Harry RA, Anderson AE, Isaacs JD, Hilkens CM. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis (2010) 69(11):2042-50. doi:10.1136/ard.2009.126383.
11. Hilkens CM, Isaacs JD. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol (2013) 172(2):148-57. doi:10.1111/cei.12038.
12. Dittel BN, Visintin I, Merchant RM, Janeway CA Jr. Presentation of the self antigen myelin basic protein by dendritic cells leads to experimental autoimmune encephalomyelitis. J Immunol (1999) 163(1):32-9.
13. Weir CR, Nicolson K, Backstrom BT. Experimental autoimmune encephalomyelitis induction in naive mice by dendritic cells presenting a self-peptide. Immunol Cell Biol (2002) 80(1):14-20. doi:10.1046/j.1440-1711.2002.01056.x.
14. Aghdami N, Gharibdoost F, Moazzeni SM. Experimental autoimmune encephalomyelitis (EAE) induced by antigen pulsed dendritic cells in the C57BL/6 mouse: influence of injection route. Exp Anim (2008) 57(1):45-55. doi:10.1538/expanim.57.45.
15. Mellanby RJ, Cambrook H, Turner DG, O'Connor RA, Leech MD, Kurschus FC, et al. TLR-4 ligation of dendritic cells is sufficient to drive pathogenic T cell function in experimental autoimmune encephalomyelitis. J Neuroinflammation (2012) 9:248. doi:10.1186/1742-2094-9-248.
16. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity (1995) 3(4):407-15. doi:10.1016/1074-7613(95)90170-1.
17. O'Connor RA, Prendergast CT, Sabatos CA, Lau CW, Leech MD, Wraith DC, et al. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J Immunol (2008) 181(6):3750-4. doi:10.4049/jimmunol.181.6.3750.
18. MacDonald AS, Straw AD, Dalton NM, Pearce EJ. Cutting edge: Th2 response induction by dendritic cells: a role for CD40. J Immunol (2002) 168(2):537-40. doi:10.4049/jimmunol.168.2.537.
19. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest (1991) 87(3):1103-7. doi:10.1172/JCI115072.
20. Branisteanu DD, Waer M, Sobis H, Marcelis S, Vandeputte M, Bouillon R. Prevention of murine experimental allergic encephalomyelitis: cooperative effects of cyclosporine and 1 alpha, 25-(OH)2D3. J Neuroimmunol (1995) 61(2):151-60. doi:10.1016/0165-5728(95)00076-E.
21. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN. 1,25-dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One (2010) 5(9):e12925. doi:10.1371/journal.pone.0012925.
22. Cantorna MT, Humpal-Winter J, DeLuca HF. Dietary calcium is a major factor in 1,25-dihydroxycholecalciferol suppression of experimental autoimmune encephalomyelitis in mice. J Nutr (1999) 129(11):1966-71.
23. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J Immunol (2005) 175(6):4119-26. doi:10.4049/jimmunol.175.6.4119.
24. Nashold FE, Miller DJ, Hayes CE. 1,25-dihydroxyvitamin D3 treatment decreases macrophage accumulation in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol (2000) 103(2):171-9. doi:10.1016/S0165-5728(99)00247-7.
25. Nashold FE, Spach KM, Spanier JA, Hayes CE. Estrogen controls vitamin D3-mediated resistance to experimental autoimmune encephalomyelitis by controlling vitamin D3 metabolism and receptor expression. J Immunol (2009) 183(6):3672-81. doi:10.4049/jimmunol.0901351.
26. Spach KM, Pedersen LB, Nashold FE, Kayo T, Yandell BS, Prolla TA, et al. Gene expression analysis suggests that 1,25-dihydroxyvitamin D3 reverses experimental autoimmune encephalomyelitis by stimulating inflammatory cell apoptosis. Physiol Genomics (2004) 18(2):141-51. doi:10.1152/physiolgenomics.00003.2004.
27. Cantorna MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A (1996) 93(15):7861-4. doi:10.1073/pnas.93.15.7861.
28. Nashold FE, Hoag KA, Goverman J, Hayes CE. Rag-1-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J Neuroimmunol (2001) 119(1):16-29. doi:10.1016/S0165-5728(01)00360-5.
29. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res (2006) 83(7):1299-309. doi:10.1002/jnr.20826.
30. Meehan TF, DeLuca HF. The vitamin D receptor is necessary for 1alpha,25-dihydroxyvitamin D(3) to suppress experimental autoimmune encephalomyelitis in mice. Arch Biochem Biophys (2002) 408(2):200-4. doi:10.1016/S0003-9861(02)00580-5.
31. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol (2011) 10(8):745-58. doi:10.1016/S1474-4422(11)70149-1.
32. Aktas O, Kury P, Kieseier B, Hartung HP. Fingolimod is a potential novel therapy for multiple sclerosis. Nat Rev Neurol (2010) 6(7):373-82. doi:10.1038/nrneurol.2010.76.
33. Mellanby RJ, Thomas DC, Lamb J. Role of regulatory T-cells in autoimmunity. Clin Sci (Lond) (2009) 116(8):639-49. doi:10.1042/CS20080200.
34. Stoop JN, Harry RA, von Delwig A, Isaacs JD, Robinson JH, Hilkens CM. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum (2010) 62(12):3656-65. doi:10.1002/art.27756.
35. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology (2010) 74(23):1852-9. doi:10.1212/WNL.0b013e3181e1cec2.
36. Ureta G, Osorio F, Morales J, Rosemblatt M, Bono MR, Fierro JA. Generation of dendritic cells with regulatory properties. Transplant Proc (2007) 39(3):633-7. doi:10.1016/j.transproceed.2006.12.032.
37. van Etten E, Dardenne O, Gysemans C, Overbergh L, Mathieu C. 1,25-dihydroxyvitamin D3 alters the profile of bone marrow-derived dendritic cells of NOD mice. Ann N Y Acad Sci (2004) 1037:186-92. doi:10.1196/annals.1337.030.
38. Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol (2000) 164(5):2405-11. doi:10.4049/jimmunol.164.5.2405.
39. Berer A, Stockl J, Majdic O, Wagner T, Kollars M, Lechner K, et al. 1,25-dihydroxyvitamin D(3) inhibits dendritic cell differentiation and maturation in vitro. Exp Hematol (2000) 28(5):575-83. doi:10.1016/S0301-472X(00)00143-0.
40. Penna G, Amuchastegui S, Giarratana N, Daniel KC, Vulcano M, Sozzani S, et al. 1,25-dihydroxyvitamin D3 selectively modulates tolerogenic properties in myeloid but not plasmacytoid dendritic cells. J Immunol (2007) 178(1):145-53. doi:10.4049/jimmunol.178.1.145.
41. van der Aar AM, Sibiryak DS, Bakdash G, van Capel TM, van der Kleij HP, Opstelten DJ, et al. Vitamin D3 targets epidermal and dermal dendritic cells for induction of distinct regulatory T cells. J Allergy Clin Immunol (2011) 127(6):1532-40.e7. doi:10.1016/j.jaci.2011.01.068.
42. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A (2002) 99(1):351-8. doi:10.1073/pnas.231606698.
43. Helft J, Böttcher J, Chakravarty P, Zelenay S, Huotari J, Schraml BU, et al. GM-CSF mouse bone marrow cultures comprise a heterogeneous population of CD11c(+)MHCII(+) macrophages and dendritic cells. Immunity (2015) 42(6):1197-211. doi:10.1016/j.immuni.2015.05.018.
44. Farias AS, Spagnol GS, Bordeaux-Rego P, Oliveira CO, Fontana AG, de Paula RF, et al. Vitamin D3 induces IDO+ tolerogenic DCs and enhances Treg, reducing the severity of EAE. CNS Neurosci Ther (2013) 19(4):269-77. doi:10.1111/cns.12071.
45. Ferreira GB, Gysemans CA, Demengeot J, da Cunha JP, Vanherwegen AS, Overbergh L, et al. 1,25-dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J Immunol (2014) 192(9):4210-20. doi:10.4049/jimmunol.1302350.
46. Stern JN, Keskin DB, Kato Z, Waldner H, Schallenberg S, Anderson A, et al. Promoting tolerance to proteolipid protein-induced experimental autoimmune encephalomyelitis through targeting dendritic cells. Proc Natl Acad Sci U S A (2010) 107(40):17280-5. doi:10.1073/pnas.1010263107.
47. Giannoukakis N, Phillips B, Finegold D, Harnaha J, Trucco M. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care (2011) 34(9):2026-32. doi:10.2337/dc11-0472.
48. Raiotach-Regue D, Grau-Lopez L, Naranjo-Gomez M, Ramo-Tello C, Pujol-Borrell R, Martinez-Caceres E, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol (2012) 42(3):771-82. doi:10.1002/eji.201141835.
49. Anderson AE, Swan DJ, Sayers BL, Harry RA, Patterson AM, von Delwig A, et al. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol (2009) 85(2):243-50. doi:10.1189/jlb.0608374.